Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.
Lymphoma
DRUG: MGCD0103
Response rate, 1 year (anticipated)
Progression-free survival, 1 year (anticipated)|Duration of objective response, 1 year (anticipated)|Safety profile, 1 year (anticipated)|Pharmacokinetics, 1 year (anticipated)|Pharmacodynamics, 1 year (anticipated)
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.